Dysmenorrhoea Efficacy Study: fixed dose combination tablets of ibuprofen and acetaminophen for primary dysmenorrhoea

Completed

You are on the General Public view
  • Source

    -
    Public Title Dysmenorrhoea Efficacy Study: fixed dose combination tablets of ibuprofen and acetaminophen for primary dysmenorrhoea
    Acronym Dysmenorrhoea Efficacy Study
    Source of Record URL http://isrctn.org/ISRCTN42521357
  • Trial

    -
    Health Condition(s) or Problem Primary dysmenorrhoea
    Lay Summary Sorry, not currently available
    Who can enter the trial 1. Female patients aged greater than or equal to 18 years 2. Primary diagnosis of primary dysmenorrhoea, with moderate-severe cramping pain in at least 4 of the previous 6 months 3. Responded to any study-specific advertising, or have indicated to staff that they wish to participate in a dysmenorrhoea trial 4. Have given written informed consent
    Who cannot enter the trial 1. A history of significant disease deemed by the investigator to render the subject unsuitable for inclusion 2. Any significant ongoing painful condition other than that associated with primary dysmenorrhoea 3. Any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of the study medication 4. A history of peptic ulcer, duodenal ulcer, gastrointestinal bleeding 5. A history of frequent dyspepsia, heartburn or indigestion 6. A history of psychotic illness, attempted suicide, or neurosis 7. A positive history of drug or alcohol abuse within the past year 8. Those taking any concomitant medications that might confound assessments of pain relief, such as psychotropic drugs, antidepressants, sedative?hypnotics taken within fives times of their elimination half lives. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if the subject has been on a stable dose for at least four weeks prior to Visit 1 (screening) and remain on this dose throughout the study. 9. Woman of childbearing potential, who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral or injectable contraceptive, an approved hormonal implant or topical patch, an intrauterine device, abstinence [should the subject become sexually active, she must agree to use a double barrier method] or condoms/diaphragm and spermicide). A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy). 10. A history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder, a significant coagulation defect, or any previous history of allergy or known intolerance to any of the drugs or formulation constituents which, in the Investigator's opinion, might preclude use of an non-steroidal anti-inflammatory drug [NSAID], including aspirin sensitive asthma or a previous allergic respresponse to a NSAID, including bronchospasm, urticaria, angioedema and rhinitis) 11. Those previously randomised into this study 12. Subjects who have received any analgesic, anti-inflammatory, antispasmodic or other therapy for dysmenorrhoea within 6 hours of taking the study medication 13. Those who have participated in a clinical trial in the previous 30 days weeks are calculated from time of last dosing in the prior trial to time of anticipated dosing in this trial 14. Those suffering with anaemia ? (blood test at screening visit) 15. Those unable, in the opinion of the investigator, to comply fully with the study requirements
    What will happen Fixed dose combination tablets of 200 mg ibuprofen plus 500 mg acetaminophen, administered as one or two tablets (two tablets equivalent to 400 mg ibuprofen plus 1,000 mg acetaminophen) in comparison to placebo. The treatments were single doses of the test medicine taken on three menstrual cycles if the pain was of sufficient intensity to need treatment. The duration of the follow-up was for up to five days after the last dose of treatment.
    Primary aim The primary analgesic efficacy endpoint will be the total pain relief over 6 hours post-dose
    Secondary Aim Total pain relief over 2 and 4 hours post-dose
    Participant Information Sheet Not available in web format, please use the contact details below to request a patient information sheet
    Website Sorry, not currently available
    Recruitment Status Completed
    Nation Wales
    Location Cardiff
  • Contact

    -
    Contact for Public Queries Prof Ronald Eccles Common Cold Centre and Healthcare Clinical Trials Unit Cardiff School of Biosciences Museum Avenue Cardiff University Cardiff CF10 3AX United Kingdom +44 (0)2920 874 102 +44 (0)2920 874 093 eccles@cardiff.ac.uk
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.